胃癌淋巴结微转移的研究进展
Research Advances of Lymph Node Micrometastasis in Gastric Cancer
DOI: 10.12677/ACM.2022.123259, PDF,    科研立项经费支持
作者: 邹若凡, 戴光荣：延安大学附属医院，陕西 延安
关键词: 胃癌；淋巴结微转移；综述文献 ；Gastric Cancer； Lymph Node Micrometastasis； Review Literature
摘要: 淋巴结转移是公认的影响胃癌预后的因素，淋巴结阴性胃癌患者预后明显优于淋巴结阳性者。然而临床中淋巴结阴性胃癌患者术后死于肿瘤复发、转移者并不在少数。淋巴结微转移(LNM)被认为是淋巴结阴性胃癌患者术后出现复发与转移的潜在原因。基于免疫组织化学、逆转录–聚合酶链式反应等的发展，淋巴结的微转移诊出率显著提高。但目前对于胃癌患者淋巴结微转移的临床意义及治疗尚未达成共识。笔者就胃癌淋巴结微转移的研究进展作一综述。
Abstract: Lymph node metastasis is a recognized factor affecting the prognosis of gastric cancer. The prognosis of gastric cancer patients with negative lymph nodes is significantly better than those with positive lymph nodes. However, there are not a few patients with lymph node-negative gastric cancer who die of tumor recurrence and metastasis after surgery. Lymph node micrometastasis (LNM) is considered to be a potential cause of recurrence and metastasis in these patients. Based on the development of immunohistochemistry, reverse transcription-polymerase chain reaction, etc., the diagnosis rate of lymph node micrometastasis has increased significantly. There is no consensus on the clinical significance and treatment of lymph node micrometastasis in patients with gastric cancer. The author reviews the research progress of gastric cancer lymph node micrometastasis.
文章引用：邹若凡, 戴光荣. 胃癌淋巴结微转移的研究进展[J]. 临床医学进展, 2022, 12(3): 1801-1806. https://doi.org/10.12677/ACM.2022.123259

参考文献

[1] Chen, W.Q., Zheng, R.S., Baade, P.D., Zhang, S.W., Zeng, H.M., Bray, F., Jemal, A., Yu, X.Q. and He, J. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. [Google Scholar] [CrossRef] [PubMed]
[2] Feng, R.-M., Zong, Y.-N., Cao, S.-M. and Xu, R.-H. (2019) Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics? Cancer Communications, 39, 22. [Google Scholar] [CrossRef] [PubMed]
[3] 王永洁, 唐洁冰, 陶冀. 淋巴结阴性胃癌患者预后影响因素的研究进展[J]. 癌症进展, 2019, 17(13): 1498-1500+1594.
[4] 刘春晓, 王海磊, 冯美燕, 王国富, 薛英威, 王宽. 检测pT1-4aN1-3M0期胃癌淋巴结微转移检测的临床意义[J].现代生物医学进展, 2015, 15(31): 6053-6056+6159.
[5] Zhou, Y., Zhang, G.-J., Wang, J., Zheng, K.-Y. and Fu, W.H. (2017) Current Status of Lymph Node Micrometastasis in Gastric Cancer. Oncotarget, 8, 51963-51969. [Google Scholar] [CrossRef] [PubMed]
[6] 李子禹, 王胤奎, 陕飞, 季加孚. 早期胃癌治疗的共识与问题[J]. 中国实用外科杂志, 2018, 38(2): 153-157.
[7] Sonoda, H. and Tani, T. (2014) Clinical Significance of Molecular Diagnosis for Gastric Cancer Lymph Node Micrometastasis. World Journal of Gastroenterology, 20, 13728-13733. [Google Scholar] [CrossRef] [PubMed]
[8] Jeuck, T.L.A. and Wittekind, C. (2015) Gastric Carcinoma: Stage Migration by Immunohistochemically Detected Lymph Node Micrometastases. Gastric Cancer, 18, 100-108. [Google Scholar] [CrossRef] [PubMed]
[9] You, X.L., Wang, Y.J., Wu, J., Liu, Q.H., Chen, D.H., Tang, D. and Wang, D.R. (2019) Aberrant Cytokeratin 20 mRNA Expression in Peripheral Blood and Lymph Nodes Indicates Micrometastasis and Poor Prognosis in Patients with Gastric Carcinoma. Technology in Cancer Research & Treatment, 18, 1-13. [Google Scholar] [CrossRef] [PubMed]
[10] Shoji, N., Takaaki, A., Yoshikazu, U. and Shigehiro, Y. (2017) Novel Surgical Approach Based on the Sentinel Node Concept in Patients with Early Gastric Cancer. Annals of Gastroenterological Surgery, 1, 180-185. [Google Scholar] [CrossRef] [PubMed]
[11] 夏加增, 孙晓光, 赵伟, 周宏, 姚路斌. 病检阴性胃癌淋巴结转移的检测: 免疫组化和RT-PCR的比较[J]. 南通大学学报(医学版), 2005(3): 164-165+168.
[12] 高洋, 李姝, 项鹏程, 虞飞, 冯立文, 岳林, 王梦琪, 白雪峰. CEA、PCK蛋白在胃癌淋巴结微转移中的表达及其临床意义[J]. 诊断病理学杂志, 2019, 26(9): 609-611.
[13] Nummela, P., Leinonen, H., Jrvinen, P., et al. (2016) Expression of CEA, CA19-9, CA125, and EpCAM in Pseudomyxoma Peritonei. Human Pathology, 54, 47-54. [Google Scholar] [CrossRef] [PubMed]
[14] 尤小兰. CK20在胃癌患者外周血、淋巴结中的表达及其对预后的预测价值[D]: [博士学位论文]. 苏州: 苏州大学, 2016.
[15] 陈宏, 余元龙, 邓庆炎, 等. 胃癌中血管内皮生长C的表达与淋巴结微转移的关系[J/CD]. 中华普通外科学文献(电子版), 2011, 5(5): 413-417.
[16] 邓庆炎, 陈宏, 雒洪志, 张倩. 血管内皮生长因子C对胃癌淋巴结转移及微转移的预测价值研究[J]. 中华普通外科学文献(电子版), 2018, 12(6): 405.
[17] 王连文, 崔艳芳, 刘敬波, 白玉, 李娜, 袁笑, 李金玲. 角蛋白18、CEA、CA19-9、CA72-4在胃癌诊断中的成本-效果分析[J]. 滨州医学院学报, 2016, 39(5): 346-349.
[18] 张明亮, 黄允宁, 卢林, 李智勇, 马强波, 马海雁, 靳丁丁, 徐远义, 赵帅, 封存志. 以CK19为标记物研究pN0胃窦癌区域淋巴结微转移[J]. 宁夏医学杂志, 2017, 39(1): 36-38.
[19] 张永乐, 薛英威, 蓝秀文, 马岩, 魏玉哲, 杨丽. 肿瘤标记物CA19-9、CEA对胃癌转移和预后预测价值的分析[J]. 哈尔滨医科大学学报, 2010, 44(2): 181-184+188.
[20] 孙洁, 孟祥军. 血清CA199、CEA、CA125、CA724联合检测在胃癌诊断中的价值[J]. 中国实验诊断学, 2014, 18(12): 1936-1939.
[21] 龚根强, 杨维桢. 术前血清CA19-9水平对胃癌患者淋巴结微转移的预测价值及其对预后的影响[J]. 中国普外基础与临床杂志, 2018, 25(1): 65-70.
[22] 许威, 刘宏斌. 血清癌胚抗原、基质金属蛋白酶3、血管内皮生长因子与胃癌微转移及预后关系的研究进展[J]. 医学综述, 2013, 19(11): 1982-1985.
[23] Zhao, F.J., Zhang, Q.Y., Kang, C.S., Cui, X.W., Wang, T., Xu, P., Zhou, X., Liu, J. and Song, X.M. (2010) Suppression of Matrix Metalloproteinase-9 Expression by RNA Interference Inhibits SGC7901 Gastric Adenocarcinoma Cell Growth and Invasion in Vitro and in Vivo. Medical Oncology, 27, 774-784. [Google Scholar] [CrossRef] [PubMed]
[24] Li, Z., Zhang, D.W., Zhang, H., Miao, Z.F., Tang, Y.X., Sun, G.P. and Dai, D.Q. (2014) Prediction of Peritoneal Recurrence by the mRNA Level of CEA and MMP-7 in Peritoneal Lavage of Gastric Cancer Patients. Tumor Biology, 35, 3463-3470. [Google Scholar] [CrossRef] [PubMed]
[25] Lee, C.M., Cho, J.-M., Jang, Y.-J., Park, S.-S., Park, S.-H., Kim, S.-J., Mok, Y.-J., Kim, C.-S. and Kim, J.-H. (2015) Should Lymph Node Micrometastasis Be Considered in Node Staging for Gastric Cancer? The Significance of Lymph Node Micrometastasis in Gastric Cancer. Annals of Surgical Oncology, 22, 765-771. [Google Scholar] [CrossRef] [PubMed]
[26] Blouhos, K., Boulas, K.A. and Hatzigeorgiadis, A. (2017) Clinical Significance of Lymph Nodes Micrometastasis in Conventionally Node-Negative Advanced Gastric Cancer. Updates in Surgery, 69, 425-426. [Google Scholar] [CrossRef] [PubMed]
[27] 吴泽宇, 彭林, 赵刚, 詹文华. 淋巴结微转移检测对判断胃癌预后的价值[J]. 实用医学杂志, 2010, 26(22): 4151-4153.
[28] 金俊蕊, 邓靖宇, 梁寒. 胃癌淋巴结分期的临床变革及分期方法的研究进展[J]. 中国肿瘤临床, 2016, 43(15): 683-689.
[29] 徐惠绵, 王鹏亮, 宫英博. 胃癌TNM分期优化及病理质量控制[J]. 中华胃肠外科杂志, 2020(1): 87-91.

为你推荐